As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s ...

Neoprobe (NYSE Amex: NEOP) remains on track to file a New Drug Application for its drug used for cancer detection, Lymphoseek, sometime in the third quarter. Factoring in the customary 10-month review ...

Earlier this month, Neoprobe (ASE: NEOP) completed the sale of its handheld gamma radiation detector business to Devicor Medical Products. The company pocketed $30 million up-front with the potential ...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its common stock has been ...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today released the text of its ...

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on September 15, Neoprobe Corp.'s Director, Peter F Drake, ...

DUBLIN, Ohio--(BUSINESS WIRE)-- On Friday, July 22, 2011, it was disclosed in a private company press release that the U.S. Food and Drug Administration (FDA) had approved use of sulfur colloid (Kit ...

Neoprobe Corp. has put all its faith in its diagnostic drugs in development by selling off the medical device that has been its primary source of revenue through nearly three decades of losses.

Devicor Medical Products, Inc. (Devicor), a portfolio company of GTCR, a leading private equity firm, announced today the completion of its previously announced agreement to acquire the neoprobe® ...

It took 17 years, but Neoprobe Corp. has turned a profit. But product development expenses and the structure of Neoprobe's contract with its marketing partner will make a trip back to the black a ...

Earlier this month, Neoprobe (AMEX: NEOP) completed the sale of its handheld gamma radiation detector business to Devicor Medical Products. The company pocketed $30 million up-front with the potential ...